Genmab announces results of Ofatumumab phase II study in MS
Genmab announces results of Ofatumumab phase II study in MS
Genmab announces 48 week results from a Phase II study of ofatumumabin RRMS.
Genmab A/S announced encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).
A total of 38 patients were included in this double-blind, dose escalation trial. Patients were randomized to receive two infusions of 100 mg, 300 mg or 700 mg of ofatumumab or placebo. After 24 weeks, the patients randomized to placebo were treated with ofatumumab and patients who were treated with ofatumumab received placebo. All patients were then followed for an additional 24 weeks. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1380 Views
-
Last post by frodo
-
- 0 Replies
- 1022 Views
-
Last post by frodo
-
- 0 Replies
- 1290 Views
-
Last post by frodo
-
- 0 Replies
- 1703 Views
-
Last post by NHE
-
- 2 Replies
- 4309 Views
-
Last post by DIM
-
- 1 Replies
- 3127 Views
-
Last post by Tif
-
- 0 Replies
- 2481 Views
-
Last post by NHE
-
- 1 Replies
- 1243 Views
-
Last post by Scott1
-
- 1 Replies
- 1927 Views
-
Last post by frodo